Oncology

Exercise can complement other treatments for prostate cancer, including androgen deprivation therapy, which can lead to significant reduction in lean mass and an increase in fat mass.

Monitoring for AEs, educating about drug regimens, and managing therapies are opportunities for pharmacists to make a difference.

According to Genentech, atezolizumab is the first and only cancer immunotherapy approved for adjuvant treatment of NSCLC.

They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.

Approximately 25% to 35% of new oncology therapies in development are oral medications.

Pembrolizumab (Keytruda) approved by FDA in combination with chemotherapy, with or without bevacizumab (Avastin), in patients with persistent, recurrent, or metastatic cervical cancer.

New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.

Abemaciclib (Verzenio) approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.

Jameshia Below, PharmD, assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how oncologic emergencies present in patients, and how each type can be recognized.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

Fluciclovine F 18 (Axumin), which is a radioactive diagnostic agent for injection that can be used to detect recurring prostate cancer.

The PROpel phase 3 trial met the primary endpoints of radiographic progressing-free for men with metastatic castration-resistant prostate when treated with Olaparib, combined with abiraterone.

There are 3 PARP inhibitors that are FDA approved in multiple settings of ovarian cancer.

The majority of treatment-related adverse events (TRAEs) were grade 1-2 in severity, and no patients experienced dose-limiting toxicities during the 28 days following initial treatment.

Allostatic load is caused by a number of different stressors, including social isolation, poverty, and racism, many of which are commonly experienced by individuals belonging to racial and ethnic minorities, according to the investigators.

Patients with cancer should not be overlooked in any pharmacy setting. These patients are in need of resources, help, and hope.

The investigators said that these cells, referred to as lymph node resident memory T cells, have been demonstrated to counteract the spread of melanoma in mice.

Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

As practices have gained experience in the post-COVID-19 environment, health care professionals have found innovative ways to work around many of the obstacles the pandemic presents.

CAR-NK therapies are also shown to have fewer adverse reactions, and 25% of mice that were treated remained disease-free.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what oncologic emergencies are and how they are classified.

Between October 2011 and February 2013, UKLS researchers randomized 4055 high-risk participants to either a single invitation to screening with LDCT or to no screening.

Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Ten quiz questions to assess your knowledge on common symptoms and treatments for prostate cancer.

Isatuximab-irfc (Sarclisa; sanofi-aventis) provides patients with another option for treatment and significantly reduces the risk of disease progression or death.

Ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease.

Oncology pharmacists can affect not only the efficacy of advancements in our health care system but also the scope of health care progress in our country.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

A single infusion of the CAR T-cell therapy Tecartus produced a high and durable response rate in heavily pretreated patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.